Compare · ADMS vs SBBP
ADMS vs SBBP
Side-by-side comparison of Adamas Pharmaceuticals, Inc. (ADMS) and Strongbridge Biopharma plc (SBBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMS and SBBP operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- ADMS is the larger of the two at $373.6M, about 2.7x SBBP ($136.0M).
- ADMS has more recent analyst coverage (5 ratings vs 0 for SBBP).
- Company
- Adamas Pharmaceuticals, Inc.
- Strongbridge Biopharma plc
- Price
- $8.21+0.61%
- $2.00+1.78%
- Market cap
- $373.6M
- $136.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Latest ADMS
- SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)
- SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.
- SEC Form 4: Bigham Michael closing all direct ownership in the company
- SEC Form 4: Mahoney David L closing all direct ownership in the company
- SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Mcfarlane Neil F. was granted 75,000 shares, closing all direct ownership in the company
- SEC Form 4: Ericson William W. closing all direct ownership in the company
- SEC Form 4: Shreedhar Vijay was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Papapetropoulos Spyridon closing all direct ownership in the company
Latest SBBP
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 15-12B filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Cohen Fredric J. returned 160,408 units of Ordinary Shares to the company, decreasing direct ownership by 50% to 160,408 units